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Abstract: This review highlights a number of nitric oxide (NO)-related mechanisms that 
contribute to coronary vascular function and that are likely affected by hypertension and thus 
become important clinically as potential considerations in prevention, diagnosis, and treatment of 
coronary complications of hypertension. Coronary vascular resistance is elevated in hypertension 
in part due to impaired endothelium-dependent function of coronary arteries. Several lines of 
evidence suggest that other NO synthase isoforms and dilators other than NO may compensate 
for impairments in endothelial NO synthase (eNOS) to protect coronary artery function, and 
that NO-dependent function of coronary blood vessels depends on the position of the vessel in 
the vascular tree. Adaptations in NOS isoforms in the coronary circulation to hypertension are 
not well described so the compensatory relationship between these and eNOS in hypertensive 
vessels is not clear. It is important to understand potential functional consequences of these 
adaptations as they will impact the efficacy of treatments designed to control hypertension and 
coronary vascular disease. Polymorphisms of the eNOS gene result in significant associations 
with incidence of hypertension, although mechanistic details linking the polymorphisms with 
alterations in coronary vasomotor responses and adaptations to hypertension are not established. 
This understanding should be developed in order to better predict those individuals at the 
highest risk for coronary vascular complications of hypertension. Greater endothelium-dependent 
dilation observed in female coronary arteries is likely related to endothelial Ca2+ control and 
eNOS expression and activity. In hypertension models, the coronary vasculature has not been 
studied extensively to establish mechanisms for sex differences in NO-dependent function. 
Genomic and nongenomic effects of estrogen on eNOS and direct and indirect antioxidant 
activities of estrogen are discussed as potential mechanisms of interest in coronary circulation 
that could have implications for sex- and estrogen status-dependent therapy for hypertension and 
coronary dysfunction. The current review identifies some important basic knowledge gaps and 
speculates on the potential clinical relevance of hypertension adaptations in factors regulating 
coronary NO function.
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Introduction to coronary hemodynamics 
in hypertension
Coronary blood flow is highly regulated to ensure an adequate matching of coronary 
perfusion to meet the metabolic demands imposed by a constantly beating heart.1–4 
The main mechanisms controlling coronary artery tone are: metabolic, myogenic, 
neurohormonal, and endothelial.1,3,4 These factors all interact to determine myocar-
dial perfusion, and the relative importance of each mechanism varies as a function of Vascular Health and Risk Management 2009:5 1076
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the anatomical location of the vessel type of interest in the 
vascular tree. For instance, large coronary arteries have a 
greater dependency on endothelium-dependent mechanisms 
for maintenance of proper tone, while smaller arterioles 
depend more on metabolic and myogenic mechanisms.2,5,6 
Vascular resistance is dependent on position in the vascular 
network with approximately 75% of the resistance lying in 
the arteries between 75–200 µm in diameter,2,5,7 and resis-
tance also varies depending on the location of the vasculature 
within the depth of the myocardium.2,5,8
Several human9–12 and experimental animal13–22 studies 
indicate that coronary vascular resistance is increased, and 
coronary flow reserve is decreased with hypertension. The 
pathophysiology of hypertension is undoubtedly heteroge-
neous and a variety of animal models have been developed to 
investigate essential hypertension. The spontaneously hyper-
tensive rat (SHR) model has been particularly useful since 
several defining characteristics of the SHR are similar to those 
observed in human essential hypertension including hemo-
dynamic abnormalities, humoral and sympathetic nervous 
system involvement, renal abnormalities and vascular cellular 
adaptations.23–28 For example, even though SHR can have 
similar coronary blood flow compared to their normoten-
sive counterpart Wistar–Kyoto rats (WKY) on a ventricular 
mass-corrected basis,13 SHRs have higher coronary vascular 
resistance (CVR) over a wide pressure range,14,19 and higher 
minimal CVR (lower maximal conductance) during maximal 
coronary vasodilation.13,16
Changes in coronary hemodynamics accompanying 
hypertension occur as a result of both structural and functional 
adaptations in the coronary vasculature. Structural remod-
eling to hypertension includes hypertrophic and eutrophic 
inward remodeling and frank rarefaction, which can result in 
loss of up to half of the normal number of microvessels.29,30 
A number of genetic, neurohumoral, and local factors 
contribute.9,11,19,29–36 to these adaptations which result in 
increases in resistance, as well as reduced flow and increased 
diffusion distances, all of which impair oxygen delivery and 
organ function. Although nitric oxide (NO) likely contributes 
to the structural remodeling accompanying hypertension, the 
focus of this review does not include description of structural 
adaptations, and the reader is referred to other works dealing 
with these topics.29,30,34,35 Rather, the current focus is on the 
contribution of vascular NO to the functional adaptations in 
the coronary circulation in hypertension.
Multiple endothelium-derived products may contribute 
to the control of the coronary vasculature.37,38 For instance, 
it is quite apparent that one or more endothelium-derived 
hyperpolarizing factors (EDHFs) contribute greatly to 
the control of the coronary microcirculation.39 Potentially 
important compensatory roles for EDHF may make these 
factors even more dominant in coronary vascular regulation 
under conditions of impairment of NO bioavailability.40–46 
The importance and emerging knowledge concerning EDHF 
notwithstanding, the focus of the current review is on NO 
and coronary adaptations to hypertension, and the reader is 
referred to the cited works for further information on EDHF 
in the coronary vasculature.
Several reports have suggested that altered NO bio-
availability contributes to altered vasomotion seen in 
hypertension38,47,48 and NO is the primary dilator of large 
epicardial coronary arteries3,6,49 as well as a mediator of flow-
induced dilation in the coronary microcirculation.2,5,6 Given 
the potential importance of the NO system in the etiology 
of hypertensive large artery disease, and given the fact that 
studies in other vascular beds have revealed a number of 
patterns of regulation of the NO system, the importance of 
which is not known in the coronary bed and in hypertension, 
it is important to bring attention to these factors as they may 
be important clinically and therapeutically. Thus, this review 
attempts to highlight a number of factors that influence NO 
function and which may be relevant from both basic science 
and clinical perspectives of understanding the function of 
the coronary circulation in hypertension.
Nitric oxide bioavailability 
in the control of coronary 
hemodynamics in hypertension
The NO synthase (NOS) inhibitor Nω-nitro-l-arginine methyl 
ester (L-NAME) has been a useful tool in studies determining 
the NO component of flow and CVR alterations in the intact 
coronary circulation. Reductions in baseline coronary flow in 
the presence of L-NAME were smaller in SHR than in WKY 
hearts,19,22 suggesting a reduced basal NO bioavailability in the 
coronary circulation of  hypertensive animals. NO bioavailability 
is a function of the production and destruction of NO, and of 
the sensitivity of the target tissue to NO.48 Further investiga-
tion revealed that the smaller L-NAME-dependent reduction 
in baseline coronary flow was not correlated to decreases 
in NO production, suggesting that increased destruction of 
NO and/or decreased sensitivity to NO contributed to the 
reduced basal coronary NO bioavailability in hypertension.22
In contrast to baseline effects, acetylcholine (ACh)-
stimulated dilation of the coronary circulation was similar in 
normotensive and hypertensive animals, and was abolished in Vascular Health and Risk Management 2009:5 1077
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both groups by L-NAME, suggesting stimulated NO release 
and/or bioavailability may be unaltered by hypertension 
in this vascular bed.50 Further analysis revealed, however, 
that the relationship between CVR and NO production is 
altered in SHR hearts so a greater amount of NO produc-
tion occurs despite a persistently much higher CVR than 
in WKY controls.18 Furthermore, inhibition of eNOS with 
l-arginine analogues also blunts constrictory responses in the 
majority of the coronary perfusion studies in hypertensive 
hearts,19,21 suggesting that NO is contributing to constrictory 
responses in the hypertensive coronary vascular bed likely 
via its destruction by superoxide and the consequent effects 
of reactive species formed.51 This is supported by observa-
tions that supplementation of the coronary perfusate with 
the superoxide scavenging enzyme superoxide dismutase 
restored the maximal endothelium-dependent dilation in 
hypertensive animals.21 Sensitivity to NO is likely not altered 
in hypertensive perfused heart studies,18,21,22 acknowledging 
some dissenting reports.52 Together this evidence suggests 
that increased NO destruction is a dominant contributor to 
the reduced NO bioavailability and consequent elevated CVR 
in the intact coronary circulation of  hypertensive animals. 
Complementary work using isolated blood vessels reveals 
additional details regarding potential mechanisms accounting 
for hypertensive adaptations in the coronary circulation.
Nitric oxide-mediated vasomotor 
function of isolated coronary 
arteries in hypertension
Studies using isolated coronary arteries and arterioles 
support the findings from the intact coronary circulation 
that endothelium-dependent dilatory function is impaired in 
hypertensive animals, and that reduced NO bioavailability, 
and increased oxidative stress contribute to the mecha-
nism of this impairment (Figure 1). Indeed, in general, 
endothelium-mediated (drug- and shear stress-stimulated) 
dilation of isolated coronary arteries is reduced in hyper-
tensive humans11,53–57 and animals,19,21,32,36,45,51,52,58–62 while the 
endothelium-independent vasodilatory responses to sodium 
nitroprusside and adenosine are often unaltered.21,32,45,55,63 
There are exceptions to these general observations18,33,50,63–66 
and the vessel type (conduit vs resistance artery),45,57 the 


































Figure 1 Factors affecting NO-mediated endothelium-dependent relaxation of coronary arteries in hypertension. Chemical and hemodynamic forces on the luminal side of 
the endothelium stimulate eNOS production of NO which can be scavenged by superoxide or diffuse to the vascular smooth muscle cells.   At the smooth muscle, available NO 
activates sGC ultimately affecting Ca2+ regulatory proteins, cytosolic [Ca2+], and contractile elements, thereby causing arterial relaxation. in hypertension, NO-bioavailability and 
relaxation of the coronary vascular smooth muscle can be altered due to many factors as discussed in the text and indicated in the Figure by the small arrows.
Abbreviations: BK, bradykinin;   ACh, acetylcholine; R, receptor; L-Arg, L-Arginine; L-Cit, L-Citrulline; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide 
synthase; nNOS, neuronal nitric oxide synthase; NO*, nitric oxide; O2*-, superoxide; ONOO-, peroxynitrite;   VSM, vascular smooth muscle; sGC, soluble guanylate cyclase.Vascular Health and Risk Management 2009:5 1078
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must be scrutinized to compare and analyze mechanisms 
of coronary vasomotor control.
Agonist-induced dilation from the pre-contracted state 
is reduced45,56,61,67 or eliminated58,68,69 by inhibitors of eNOS 
in isolated coronary vessels from hypertensive animals, 
suggesting that NO remains an important component of 
vascular function even when its bioavailability is reduced in 
hypertension. In isolated pressurized coronary microvessels 
it was observed that removal of the endothelium increased 
the amount of myogenic constriction to a greater extent in 
SHR than in WKY over a wide pressure range.31 Similarly, 
inhibition of the endothelial NOS isoform eNOS resulted 
in greater constriction in the SHR at moderate-to-high 
pressures,31 while inhibition of the cyclooxygenase (COX) 
pathway did not affect the myogenic response in either WKY 
or SHR.70 These studies suggest that NO is an important 
mediator of basal tone, especially at higher pressures, which 
are more likely to be physiologically relevant, especially in 
hypertension.
Regarding NO bioavailability in isolated arteries, while 
several reports suggest that NO production per se is not 
altered in isolated arteries from hypertensive animals,18,22,66 
a recent report indicates that hypertension is associated with 
an increase in arginase activity, which results in reduced 
basal and stimulated NO production.71 In general, however, 
increased local vascular superoxide production-induced 
destruction of NO is thought to be the major mechanism 
limiting NO bioavailability in isolated coronary vessels from 
hypertensive animals,48,72 as also seemed to be the case when 
evaluating the intact coronary vascular bed.
The reaction rate of NO and superoxide is much faster 
than that of superoxide with superoxide dismutase.47 Thus it 
is not surprising that in hypertension the increased produc-
tion of reactive oxygen species (ROS) is associated with an 
increased production of peroxynitrite in the heart and coro-
nary blood vessels.47,48,73–75 The production of peroxynitrite 
itself has an impact on several pathways of vasodilation 
including reduced prostaglandin synthesis and inhibition 
of K+ channels.8,76 Additionally peroxynitrite impairs NO 
production through oxidation of BH4, a NOS co-factor8,76–78 
and also impairs the sGC-mediated response to NO.8,76
Coronary hemodynamics 
and vasomotor activity 
in the eNOS knockout mouse
Given that hypertension is associated with impairments in 
NO bioavailability in the coronary vasculature as illustrated 
above, it is instructive to consider whether experimental 
models that specifically disrupt NO availability can provide 
insight to help understand and interpret hypertensive 
adaptations. One such model is the eNOS knockout mouse. 
Early work by Huang and colleagues demonstrated an 
increase in blood pressure (∼20 mm Hg) in eNOS knockout 
(eNOS-/-) compared to wild-type (WT) mice,79 and subse-
quent studies have demonstrated that the blood pressure 
effect is age-dependent; absent at eight weeks, but elevated 
by up to ∼50 mm Hg at 12 weeks.80,81 These observations are 
consistent with the general view that NO is of critical impor-
tance in controlling vascular resistance and blood pressure.
The coronary vasculature of WT mice depends on NO 
for the majority of its overall total endothelium-dependent 
dilation since acute NOS inhibition eliminates most of the 
ACh-induced dilation in isolated preparations of the left ante-
rior descending and left circumflex coronary arteries82,83 and 
about half of the bradykinin (BK)-induced dilation in isolated 
heart preparations.44 However, in the eNOS-/-, overall total 
endothelium-dependent dilation of the coronary vasculature 
can be either unaltered,83 reduced,44 or eliminated82 when 
compared to WT littermates. Since dilatory responses to 
endothelium-independent dilators in eNOS-/- are identical 
to those in WT in both isolated vessels82,83 and perfused heart 
preparations,40,44 these results suggest that alterations occur 
in the eNOS-/- as a result of changes in the activity of other 
endothelium-derived vasodilators to compensate for the loss 
of eNOS-derived NO.
Little consensus has been reached as to the chemical 
identity of the dilator(s) released from the endothelium 
in eNOS-/-. Possibilities include NO (derived from other 
NOS isoforms; iNOS, nNOS), prostacylin, and non-NO, 
nonprostanoid endothelium-derived dilators.42 For instance, 
in isolated coronary arteries, the specific nNOS inhibitor 
trifluoromethylphenylimidazole (TRIM) significantly 
reduced ACh-induced dilation in eNOS-/- by approximately 
half, and additional COX inhibition with indomethacin 
almost completely eliminated this remaining ACh-induced 
dilation. In contrast, neither inhibitor affected the responses 
in WT vessels.83 This suggests that nNOS-derived NO and 
prostacyclin may compensate for the loss of eNOS in eNOS-/- 
to preserve coronary artery endothelium-dependent dilation. 
It is also possible that upregulation of cytochrome-P450 
metabolites may be responsible for some of the compensatory 
endothelium-dependent dilation observed in the eNOS-/- 
coronary vasculature.44
Thus, although it is clear that overall endothelium-dependent 
dilation may be maintained in eNOS-/- via compensatory Vascular Health and Risk Management 2009:5 1079
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changes in alternate dilatory pathways, the precise mechanisms 
signaling this compensation by alternate pathways is not 
resolved and seems to involve multiple factors.42 The hyper-
tension itself, and the compensatory changes in endothelium-
derived vasoactive pathways that occur in the eNOS-/- model 
must be accounted for in studies utilizing this model to 
study the importance of eNOS and adaptations of the coro-
nary circulation to hypertension. Known responses of NOS 
isoforms in hypertension may help to determine the mecha-
nisms controlling compensatory responses in the regulation 
of coronary endothelial function. It could be important to 
understand this issue for the effective clinical/therapeutic 
management of vascular dysfunction in hypertension and 
other cardiovascular disease.
Adaptations in coronary NOS 
isoforms to hypertension
The NOS family of enzymes is composed of three isoforms; 
neuronal nNOS, inducible iNOS, and endothelial eNOS.84 
For all isoforms, NO production is controlled through 
protein expression level, and a number of post-translational 
mechanisms; however, many regulatory mechanisms are 
isoform-specific.84 In terms of coronary vascular control in 
hypertension and heart failure, eNOS is the major isoform 
of interest, and is expressed in the coronary endothelium, the 
endocardium, and in cardiomyocytes;85,86 however, nNOS and 
iNOS may also play a role in vascular control under certain 
conditions (Figure 1),87–90 as alluded to above.83
eNOS
Observations that eNOS expression level of coronary artery 
endothelium,52 and intramyocardial arterioles19 are reduced in 
SHR vs WKY animals have led to the suggestion that reduced 
eNOS expression contributes to the coronary endothelial 
dysfunction accompanying hypertension. However, other 
studies report that eNOS expression is actually increased 
in the coronary vessels in hypertension, suggesting that 
compensatory upregulation of this enzyme may be a strategy 
to help preserve vascular function.85
In contrast to the disparate findings regarding coronary 
eNOS expression in hypertension,19,52,85,88 eNOS levels 
in large systemic arteries such as the aorta are generally 
increased in hypertensive rats.48 For example, eNOS protein 
expression was elevated by ∼60% in male SHR compared 
to WKY thoracic aorta.91 Although eNOS expression is 
elevated in the SHR aorta, the elevated ROS environment 
because of increased NAD(P)H oxidase expression48 may 
scavenge the available NO, and/or uncoupled eNOS could 
be producing ROS rather than NO,92 both of which would 
lead to the impaired NO-mediated dilation. The importance 
of these mechanisms in the coronary circulation in hyperten-
sion has not been resolved. In this regard, it will be important 
to assess the susceptibility of the coronary vascular bed to 
ROS-mediated reductions in NO bioavailability in hyperten-
sion via the actions of ROS sources such as NADPH oxidase 
and possibly uncoupled NOS activity.
Uncoupled eNOS has been the subject of several exten-
sive reviews.76–78,93 Briefly, this process is a result of reduced 
substrate l-arginine or cofactor BH4. Under either of these 
conditions the flow of electrons is delivered to molecular 
oxygen and superoxide is formed.76–78,93 In hypertensive 
animals chronic treatment with BH4 has been shown to 
improve endothelium-dependent dilation though this treat-
ment both increased NO production and reduced superoxide 
production.74,94 These results suggest that at least part of 
the increased production of ROS and altered vasodilation 
may be explained by increased uncoupled eNOS-mediated 
production of superoxide, and subsequent reduced NO 
bioavailability. The reduction in BH4 and/or increase in 
arginase71 may propagate the uncoupling of eNOS and 
enhance superoxide production under these conditions. 
It needs to be determined if uncoupled eNOS contributes to 
suppression of NO bioavailability in the coronary vascular 
bed in hypertension in order to determine if this should 
be a potentially important treatment target to correct the 
vascular dysfunction.
iNOS
The potential role for iNOS as a vasoactive NO source in the 
coronary vasculature of hypertensive animals is supported 
by observations of increased iNOS expression in many SHR 
tissues (including heart) which is attenuated by antioxidant 
treatment.88 However, other studies show that iNOS activity 
is either no different between SHR and WKY,85 or completely 
undetectable in either strain.95 Similarly, in dogs with acute 
perinephritic hypertension, iNOS protein is undetectable 
in the heart and no difference in Ca2+-independent NOS 
activity is apparent between normotensive and hypertensive 
conditions.86 Thus, the contribution of iNOS to altered NO 
production in hypertension remains unknown at this time. 
The involvement of iNOS may be complex, as this isoform is 
known to act in an uncoupled manner, producing superoxide 
in some diseased arteries (Figure 1).90 It is also possible that 
the reduction in both BH4 and l-arginine could account for 
increased superoxide production from uncoupled iNOS, 
as described above for eNOS.Vascular Health and Risk Management 2009:5 1080
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nNOS
Isolated left anterior descending coronary arteries from 
eNOS-/- exhibit similar overall total endothelium-dependent 
dilation in response to increased flow as do those from WT.89 
Flow-induced dilation of eNOS-/- coronary arteries was 
inhibited by the nNOS specific inhibitor 7-nitroindazole 
(7-Ni), and by the soluble guanylate cyclase (sGC) inhibitor 
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) to a 
similar extent as by L-NAME.89 However, while L-NAME 
inhibited dilation in WT, 7-Ni had no effect in WT, sug-
gesting that the vasodilatory role for nNOS-derived NO 
was limited to conditions under which NO availability from 
eNOS is impaired (ie, the eNOS-/-), similar to the findings 
of a previous report that used the nNOS inhibitor TRIM to 
demonstrate a vasodilatory contribution of nNOS in isolated 
coronary arteries of eNOS-/- but not WT.83 The presence of 
nNOS protein in the coronary endothelium of eNOS-/-, but 
not in WT animals89 supports the functional findings. Thus, 
in the absence of eNOS, nNOS may be upregulated, and 
act through sGC to help maintain coronary flow-mediated 
dilation. This reveals a possible compensatory role for 
nNOS in the control of coronary vascular function in hyper-
tension, especially if the elevated blood pressure associated 
with eNOS-/- is involved in signaling the increase in nNOS 
expression.83
The work with knockout animals and with isoform-
specific pharmacological blockade reveals that shifts can 
occur in the origin of NO in the coronary vasculature under 
conditions of impairment of eNOS function and of oxidative 
stress, such as occurs in a variety of cardiovascular diseases 
including hypertension. Currently, these adaptations are 
predominantly interpreted as compensatory changes to 
protect NO bioavailability under the indicated conditions. 
The findings highlight an important response that must 
be taken into account to understand the role of NO in 
coronary vascular adaptations to hypertension and in thera-
peutic interventions designed to protect coronary vascular 
function. Factors affecting individual variability in eNOS 
regulation could impact these considerations, including 
emerging evidence that gene polymorphisms in eNOS are 
associated with cardiovascular disease risk.
eNOS polymorphisms associated 
with hypertension and coronary 
vascular function
Gene polymorphisms in eNOS and resultant impacts on 
eNOS expression levels have been associated with increased 
risk of hypertension,96 as well as a variety of conditions 
affecting the coronary circulation including coronary artery 
disease and coronary spasm.97 However, little evidence is 
available regarding the precise mechanisms by which eNOS 
polymorphisms may lead to altered levels of cardiovascular 
disease. Although a variety of locus- and ethnicity-dependent 
polymorphism effects exist,97 the current review will briefly 
focus specifically on the single nucleotide polymorphisms 
and grouped haplotypes that are associated with hyperten-
sion, and the limited known effects on coronary vascular 
function (Figure 2).
An exon 7 polymorphism results in eNOS Glu298Asp, 
with the Glu298Asp variant associated with 2.3X greater 
odds of developing hypertension.96,97 Several recent studies 
also associate eNOS combined haplotypes of the T-786C, 
Glu298Asp, and intron 4 polymorphisms with incidence 
of hypertension and plasma NO metabolites,98,99 implying 
a functional change at the eNOS enzyme. Available infor-
mation suggests that eNOS polymorphisms attenuate the 
eNOS promoter efficiency.100,101 However, combinations of 
single polymorphisms can interact in a complex manner, and 
this supports the need to investigate haplotypes in order to 
assess and understand the role of eNOS polymorphisms in 
hypertension and vascular function.101
Although eNOS polymorphisms and altered coronary 
eNOS expression are associated with hypertension,96,98,99 
little direct evidence links mutations in the eNOS gene to 
specific mechanisms of coronary vascular dysfunction in 
hypertension. Certain polymorphisms for the 27 bp repeat 
at intron 4 and for the G894T have been associated with 
alterations in coronary vasomotor responses,102,103 but this 
has not been assessed in a manner that allows for conclu-
sions regarding the endothelium, or NO-dependency of 
the response. Thus, the precise mechanisms by which 
eNOS polymorphisms might affect coronary vascular 
function in hypertension have not yet been well estab-
lished, and this important issue remains to be elucidated 
experimentally. In light of the involvement of NO in 
coronary hemodynamic and vasomotor adaptations to 
hypertension established in the previous sections, it is 
likely that human eNOS polymorphisms will be a factor 
contributing to the overall coronary vascular endothelial 
dysfunction accompanying hypertension in humans. Knowl-
edge of the eNOS polymorphism status could be of possible 
diagnostic and therapeutic utility in the management of 
individual hypertensive patients as it may provide useful 
information concerning the potential severity of coronary 
vascular dysfunction.Vascular Health and Risk Management 2009:5 1081
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Heterogeneity of eNOS expression 
in the coronary vascular bed
As might be expected from the known dependency of vasomo-
tor control mechanisms on the position of a given vessel type 
in the vascular tree,2,5,6 the distribution of the eNOS protein is 
likewise not uniform throughout the coronary vasculature of 
normal healthy hearts. Laughlin and colleagues demonstrated 
a reduced eNOS protein content per mg total vessel protein in 
the smallest porcine coronary resistance arteries (50 µM) 
compared to larger coronary arteries, despite a large reduction 
in the smooth muscle cell-to-endothelial cell ratio as coro-
nary artery diameter decreases.104 These data suggest that the 
largest coronary conduit vessels have a very large expres-
sion of eNOS protein in each endothelial cell. The authors 
postulate that the greater eNOS content in conduit arteries 
may be necessary to provide adequate NO for dilation of 
multiple layers of vascular smooth muscle, or may provide NO 
for dilation of downstream vessels.104  The reported expres-
sion pattern for eNOS is consistent with a greater depen-
dence on NO-mediated, endothelium-dependent dilation in 
larger arteries compared to the smallest arterioles.2,5,6
The coronary artery is characterized by asynchronous 
hemodynamics, wherein the wall shear stress from blood 
flow is out of phase with the circumferential strain from blood 
pressure105 and this may play a role in determining the hetero-
geneous eNOS expression in the coronary arterial tree.106,107 
Further support for the role of  hemodynamics in eNOS protein 
expression comes from studies in miniature swine following 
prolonged aerobic exercise training.108 Following weeks 
of training, eNOS protein content was increased by over 
50% in coronary arteries and small and large arterioles, but 
unaltered in coronary conduit and intermediate arterioles,108 
suggesting that steady state adaptations to exercise hemody-
namic stimuli include nonuniform changes in eNOS expres-
sion that lead to an NO-mediated improvement in coronary 
resistance artery endothelium-dependent dilation.109
Thus, eNOS protein expression is nonuniformly distrib-
uted throughout the coronary vasculature, possibly as the 
result of local hemodynamic influences, and eNOS expres-
sion may be altered in response to changes in coronary hemo-
dynamics caused by exercise (Figure 2). The hemodynamics 
of the coronary circulation are altered in hypertension9,59 and 
likely affect the distribution of eNOS expression throughout 
the coronary vasculature. Whether the heterogeneous distri-
bution of eNOS and NO-mediated vasomotor activity in the 
coronary vasculature may be altered by hypertension, and the 
mechanisms responsible have not been directly tested. If so, 
there may be implications for the loci of NO dependent events 
such as blood flow control, thrombosis, adhesion and cellular 
infiltration, and VSM hypertrophy and proliferation.
Sex-dependent function 
of the coronary vasculature 
and the role of estrogen
It is widely recognized that young adult females compared 
to males or postmenopausal females have a lower incidence 
























Figure 2 effects of genetic factors and estrogen on eNOS function and NO bioavailability in coronary arteries with hypertension. Activation of the membrane-bound 
estrogen receptor can increase eNOS expression and activation as well as reduce the destruction of NO by superoxide, thereby increasing NO available for relaxation. Local 
hemodynamics, location in the coronary vascular bed, and genetic polymorphisms can also affect eNOS expression and may impact coronary relaxation in hypertension.
Abbreviations: R, receptor; eR, estrogen receptor;   AT1, type 1 angiotension ii receptor;  NO, nitric oxide; O2*-, superoxide; ONOO-, peroxynitrite; MAPK, mitogen-activated 
protein kinase;   Akt, protein kinase B.Vascular Health and Risk Management 2009:5 1082
Levy et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
of morbidity and mortality from coronary artery disease.110 
It is likely that sex-dependent differences in vascular endothe-
lial function contribute to this phenomenon. Direct studies of 
coronary vascular endothelium function have demonstrated 
greater maximal relaxations and sensitivity to endothelium-
dependent agonists in isolated coronary arteries from healthy 
female compared to male pigs.111 Furthermore, increases in 
intravascular pressure elicited smaller myogenic constrictions 
in isolated rat coronary arteries from females compared to 
males, and the larger diameters of the female coronary arteries 
were associated with higher endothelial Ca2+ concentrations 
and eNOS activity.112 Elevated NO release from female 
compared to male coronary arteries has been observed in a 
number of studies,113–115 and is consistent with findings in a 
variety of other artery types.
There is also a consistent sex-dependent effect in the 
endothelium-dependent NO-mediated vasorelaxation in 
hypertensive rats. Thus, although both male and female SHR 
have lower endothelium-dependent relaxation responses in 
isolated aortas compared to their respective normotensive 
WKY counterparts, ACh elicited greater relaxations in 
female than in male SHR aorta.116,117 Furthermore, whereas 
high ACh concentrations result in re-contractions of isolated 
aortic segments from male SHR, this response did not occur 
in aortas of female SHR.116,117 This general response was also 
observed in isolated aortas of stroke-prone SHR.118 These 
sex-dependent functional effects have not been studied in 
the coronary circulation of hypertensive animals. It would 
be valuable to systematically assess this and to determine the 
mechanisms accounting for sex-differences in the coronary 
vascular function in order to better understand the molecular 
and functional basis for sex differences in vascular disease, 
and to provide foundation for possible sex-dependent diag-
nostic and treatment strategies.
It is possible that estrogen-independent mechanisms 
contribute to sex differences in endothelium-dependent 
vasomotor function and eNOS expression and activity, but 
there is general consensus that estrogen is a major signal coor-
dinating the sex-dependent vascular function and phenotype 
(Figure 2).119–121 Estrogen treatment has been demonstrated 
to enhance coronary blood flow,122–125 endothelial eNOS 
expression and activity levels,126–129 and NO release.114,125,130,131 
Estrogen’s effect on endothelium NO-mediated action may 
occur by endothelium dependent genomic, nongenomic, 
and antioxidant mechanisms in the coronary vasculature. 
Although these specific mechanisms have not been examined 
extensively in hypertension models, the following sections 
briefly outline evidence for these mechanisms affecting 
the coronary vascular bed, and are intended to provide 
provocation for further study in the context of sex-dependent 
coronary vascular phenotypes in hypertension.
endothelium-dependent genomic action 
of estrogen in the coronary vasculature
Activation of estrogen receptors (ER) mediates the upregula-
tion of eNOS128,132 via a specific estrogen response element in 
the eNOS gene promoter region (Figure 2).133 Muller-Delp and 
colleagues demonstrated that estrogen treatment increased 
eNOS protein in coronary arteries of ovariectomized ERα-
deficient mice.134 However, eNOS levels were not restored 
to those seen in estrogen-treated ovariectomized wild-type 
mice, suggesting partial control through ERα and ERβ. 
In human coronary artery endothelial cells, 17β-estradiol 
treatment resulted in significantly increased eNOS protein 
levels and attendant elevations in basal and A23187-induced 
NO release,135 effects which were completely inhibited in 
the presence of ICI182,780, a specific estrogen-receptor 
antagonist. Collectively, these and other studies indicate 
that genomic effects of estrogen on eNOS expression could 
influence coronary vascular function and account for sex-
differences. Application of this knowledge to studies of the 
coronary vascular bed of hypertensive individuals should 
be undertaken to assess whether these effects occur or are 
disrupted in hypertension and when estrogen status changes 
in hypertensive individuals.
endothelium-dependent nongenomic 
action of estrogen in the coronary 
vasculature
At physiological concentrations, estrogen can modulate 
vascular tone by inducing rapid release of NO from the endo-
thelium that is not dependent on eNOS transcription (Figure 2). 
For instance, 15 min of intracoronary 17β-estradiol infusion 
potentiated coronary microvascular vasodilator responses 
to ACh in postmenopausal women in an endothelium-
dependent manner.136 Animal models support this nongenomic 
activation of eNOS potentiating endothelium-dependent 
vasodilation.126,129 Although enhanced basal NO levels in 
the female coronary vasculature have been attributed to sex 
differences in Ca2+-handling mechanisms of the vascular 
endothelium,112 the stimulation of NO production during 
estrogen administration has also been reported to occur 
independently of Ca2+ mobilization.137 This mechanism likely 
involves a functional signaling unit localized in the endothelial 
plasmalemmal caveolae where ERs and eNOS are found.138 Vascular Health and Risk Management 2009:5 1083
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Estrogen binding thus leads to eNOS phosphorylation via 
ERK1/2 and PI3-kinase/Akt-dependent pathways. Rapid release 
of NO occurs once eNOS has dissociated from caveolin-1 
and united with the scaffolding protein Hsp90.137 Regardless 
of the particular cell signaling mechanisms involved, these 
preliminary findings suggest an acute sensitivity to changes 
in estrogen that may have functional impact in the coronary 
circulation. It could be important to know whether this plays 
a role in heterogeneity between sexes and within females with 
different estrogen status, with respect to the overall control 
of the coronary vascular bed in hypertension as this could 
affect prevention, diagnosis and treatment decisions.
Antioxidant effects of estrogen 
on the coronary vasculature
The specific mechanisms of estrogen’s antioxidant effect 
are likely manifold and likely involve both genomic and 
nongenomic motifs.133 One intriguing possibility related 
to vascular adaptations in hypertension involves potential 
effects of estrogen on AII-induced NAD(P)H oxidase 
activity.139 Pretreatment of bovine coronary microvascular 
endothelial cells with 17β-estradiol prevented increases in 
NAD(P)H oxidase expression observed after 24 hours of 
AII stimulation alone. Inhibition of ERs by ICI182,780 did 
not alter the estradiol-induced decrease in AII-stimulated 
NAD(P)H expression, suggesting that the effect of estrogen 
was not ER-mediated.139 However, estrogen administration 
did prevent AII-induced increases in type 1 angiotensin II 
receptors (AT1).139 It has been proposed that estrogen’s anti-
oxidant effects may be mediated via this down-regulation of 
AT1 receptors, causing decreased superoxide anion produc-
tion and improved NO bioavailability. This estrogen signaling 
may occur via non-ER-dependent modulation of either the 
endothelial membrane properties, or via chemical antioxidant 
properties of estrogen itself.140 Regardless of the specific 
mechanism linking estrogen to NAD(P)H oxidase expression 
in coronary vascular endothelium, these observations seem 
to be of great importance in the context of hypertension, as 
upregulation of vascular cell NAD(P)H oxidase is the major 
source of elevated vascular ROS which are thought to make 
a large contribution to the endothelial dysfunction accom-
panying hypertension.48,72 Thus, this mechanism should be 
of interest in examining potential sex-dependent coronary 
vascular adaptations in hypertension.
Summary
Many specific details regarding the regulation of NO bio-
availability in the coronary vascular bed in hypertension 
are still unclear. Compensations, both from non-NO 
endothelium-derived vasodilators, and possibly by other iso-
forms of NOS occur when eNOS functionality is impaired. 
There is some evidence that similar compensations may 
occur in hypertension, but much more research is required 
to define mechanisms of the compensatory changes and 
to describe the signals associated with hypertension that 
trigger these changes. Polymorphisms of eNOS have been 
associated with hypertension incidence, and some emerging 
data suggest that coronary vascular function is also associ-
ated with certain eNOS polymorhisms; although these are 
promising findings, again the mechanistic details linking 
eNOS polymorphisms with coronary vascular function in 
hypertension remain to be rigorously established. Changes 
in endothelium-dependent function contribute to sex differ-
ences in cardiovascular disease. It has been demonstrated 
that estrogen has several mechanisms of action that improve 
NO bioavailability, including some known to be altered in 
hypertension.
Based on known functional effects of the identified 
factors that regulate coronary vascular NO mechanisms, 
it is intriguing to speculate that these will also be impor-
tant mechanisms in the coronary vascular adaptations to 
hypertension. Basic information concerning compensatory 
vasodilator pathways, NOS isoform shifts, eNOS polymor-
phisms and sex- and estrogen status-dependent effects on 
NO bioavailability may be very helpful in designing more 
effective prevention, diagnostic and therapeutic strategies to 
deal with coronary vascular dysfunction in hypertension and 
cardiovascular disease.
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